KARI BRAUN WISINSKI

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology MADISON, WI NPI 1982895751

General Payments — all program years on this page

$36,524.77

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 29
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $12,253.90 across 11 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Stemline Therapeutics Inc. $6,976.656
Gilead Sciences, Inc. $2,995.872
PFIZER INC. $1,750.001
Acerta Pharma LLC $531.382

By program year

Program yearAmountRecords
2018 $184.403
2020 $2,501.142
2021 $11,234.425
2022 $4,164.113
2023 $6,186.805
2024 $12,253.9011

Records — PY2024 (11)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104215845 AstraZeneca Pharmaceuticals LP $35.35 02/22/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105698254 AstraZeneca Pharmaceuticals LP $496.03 02/06/2024 Compensation for serving as faculty or as a speaker for a medical education program Undisputed 01/23/2026 View at CMS
1131480949 PFIZER INC. $1,750.00 02/01/2024 Honoraria Undisputed 01/23/2026 View at CMS
1133600101 Gilead Sciences, Inc. $2,880.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1133831927 Gilead Sciences, Inc. $115.87 06/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142961171 Stemline Therapeutics Inc. $2,220.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1142961173 Stemline Therapeutics Inc. $431.00 07/12/2024 Honoraria Undisputed 01/23/2026 View at CMS
1142961175 Stemline Therapeutics Inc. $137.72 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142961177 Stemline Therapeutics Inc. $117.93 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142961179 Stemline Therapeutics Inc. $1,850.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1142961181 Stemline Therapeutics Inc. $2,220.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.